Imaging-Based Biomarkers Predict Programmed Death-Ligand 1 and Survival Outcomes in Advanced NSCLC Treated With Nivolumab and Pembrolizumab: A Multi-Institutional Study

Authors:

Abstract
No abstract available
Funding Information
  • Santé

This publication has 31 references indexed in Scilit: